The domain within your query sequence starts at position 5 and ends at position 434; the E-value for the HgmA domain shown below is 2e-225.
KYISGFGNECASEDPRCPGSLPKGQNNPQVCPYNLYAEQLSGSAFTCPRNTNKRSWLYRI LPSVSHKPFESIDQGHVTHNWDEVGPDPNQLRWKPFEIPKASEKKVDFVSGLYTLCGAGD IKSNNGLAVHIFLCNSSMENRCFYNSDGDFLIVPQKGKLLIYTEFGKMSLQPNEICVIQR GMRFSVDVFEETRGYILEVYGVHFELPDLGPIGANGLANPRDFLIPVAWYEDRRVPGGYT VINKFQGKLFACKQDVSPFNVVAWHGNYTPYKYNLENFMVINAVAFDHADPSIFTVLTAK SLRPGVAIADFVIFPPRWGVADKTFRPPYYHRNCMSEFMGLIKGHYEAKQGGFLPGGGSL HSAMTPHGPDADCFEKASKAKLEPERIADGTMAFMFESSLSLAVTKWGLKTCSCLDENYY KCWEPLRSHF
HgmA |
---|
PFAM accession number: | PF04209 |
---|---|
Interpro abstract (IPR005708): | Alkaptonuria (AKU), a rare hereditary disorder, was the first disease to be interpreted as an inborn error of metabolism. The deficiency causes homogentisic aciduria, ochronosis, and arthritis. AKU patients are deficient for homogentisate 1,2 dioxygenase ( EC 1.13.11.5 ), the enzyme that mediates the conversion of homogentisate to maleylacetoacetate; a step in the catabolism of both tyrosine and phenylalanine. |
GO process: | oxidation-reduction process (GO:0055114), L-phenylalanine catabolic process (GO:0006559), tyrosine metabolic process (GO:0006570) |
GO function: | homogentisate 1,2-dioxygenase activity (GO:0004411) |
This is a PFAM domain. For full annotation and more information, please see the PFAM entry HgmA